Qaialdo

Qaialdo is a medicine used to manage refractory oedema (swelling due to fluid build-up that does not respond to standard treatments) associated with any of the following conditions: - congestive heart failure (when the heart does not pump blood as well as it should and fluid builds up around the heart and in the legs); - hepatic cirrhosis (liver scarring) with ascites (fluid build-up in the belly) and oedema (fluid build-up in the legs, feet and ankles); - malignant ascites (ascites caused by cancer cells spreading to the organs in the belly); - nephrotic syndrome (a group of symptoms associated with kidney damage, such as the presence of protein in the urine or oedema); - essential hypertension (high blood pressure without a known cause). It can also be used to diagnose and treat primary aldosteronism, a condition in which the body produces too much of the hormone aldosterone, which also results in oedema. Qaialdo is a ‘hybrid medicine’. This means that the medicine is similar to a ‘reference medicine’ containing the same active substance, but Qaialdo is available as a liquid to be taken by mouth while the reference medicine is available as tablets. The reference medicine for Qaialdo is Aldactone. Qaialdo contains the active substance spironolactone.